Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

The global Liquid Biopsy Market, valued at US$5.9 billion in 2023, is forecasted to grow at a robust CAGR of 11.9%, reaching ...

This report describes and explains the liquid biopsy for cancer diagnostics market and covers 2019-2024, termed the historic ...

The recent wildfires in Los Angeles are just the latest in a series of natural disasters that have disrupted cancer care.

Natera Inc. poached Guardant Health Inc. employees to steal trade secrets and jumpstart its “lagging position” in the early cancer test industry, according to a federal lawsuit. Former Guardant ...

Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test. AUSTIN, Texas, January 17, 2025--Natera, Inc. (NASDAQ: NTRA), a ...

Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

Piper Sandler analyst David Westenberg raised the firm’s price target on Guardant Health (GH) to $50 from $34 following quarterly results. The ...